NCT01534897View on ClinicalTrials.gov

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

NACompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Papillary Thyroid Carcinoma

Interventions

DRUG

GSK2118436

150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)

Trial Locations (1)

02215

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Massachusetts General Hospital

OTHER